MA32080B1 - Vaccine comprising a ribosomal protein extract (rpe) and optionally an adjuvant promoting the th1 response - Google Patents

Vaccine comprising a ribosomal protein extract (rpe) and optionally an adjuvant promoting the th1 response

Info

Publication number
MA32080B1
MA32080B1 MA33087A MA33087A MA32080B1 MA 32080 B1 MA32080 B1 MA 32080B1 MA 33087 A MA33087 A MA 33087A MA 33087 A MA33087 A MA 33087A MA 32080 B1 MA32080 B1 MA 32080B1
Authority
MA
Morocco
Prior art keywords
rpe
optionally
response
vaccine
ribosomal protein
Prior art date
Application number
MA33087A
Other languages
Arabic (ar)
French (fr)
Inventor
Manuel Soto Álvarez
Daniel Ruiz Abánades
Carlos Alonso Bedate
Original Assignee
Leti S L Unipersonal Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leti S L Unipersonal Lab filed Critical Leti S L Unipersonal Lab
Publication of MA32080B1 publication Critical patent/MA32080B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La présente invention concerne une composition comprenant un rpe et facultativement un adjuvant promouvant la réponse th1 pour la préparation d'un médicament destiné au traitement ou à la prévention d'une maladie parasitaire, ainsi que son utilisation.The present invention relates to a composition comprising a rpe and optionally an adjuvant promoting the th1 response for the preparation of a medicament for the treatment or prevention of a parasitic disease, as well as its use.

MA33087A 2008-01-18 2010-08-13 Vaccine comprising a ribosomal protein extract (rpe) and optionally an adjuvant promoting the th1 response MA32080B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2192808P 2008-01-18 2008-01-18
EP08100634 2008-01-18
PCT/EP2009/050334 WO2009090175A1 (en) 2008-01-18 2009-01-14 Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant

Publications (1)

Publication Number Publication Date
MA32080B1 true MA32080B1 (en) 2011-02-01

Family

ID=39471089

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33087A MA32080B1 (en) 2008-01-18 2010-08-13 Vaccine comprising a ribosomal protein extract (rpe) and optionally an adjuvant promoting the th1 response

Country Status (20)

Country Link
US (1) US20110020405A1 (en)
EP (2) EP2570427A1 (en)
JP (2) JP2011509968A (en)
CN (1) CN101977930B (en)
AP (1) AP3007A (en)
AU (1) AU2009204849B2 (en)
BR (1) BRPI0906787A2 (en)
CA (1) CA2712475A1 (en)
CO (1) CO6280495A2 (en)
DK (1) DK2231700T3 (en)
ES (1) ES2486365T3 (en)
HK (1) HK1150291A1 (en)
HR (1) HRP20140447T1 (en)
MA (1) MA32080B1 (en)
MX (1) MX2010007831A (en)
PL (1) PL2231700T3 (en)
PT (1) PT2231700E (en)
RU (1) RU2521499C2 (en)
WO (1) WO2009090175A1 (en)
ZA (1) ZA201005143B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA110310855B1 (en) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal The Use of an l3 and/or l5 Source as a Vaccine or as a Diagnostic for a Parasitic Disease
EP2638062B1 (en) 2010-11-10 2018-04-25 Laboratorios LETI, S.L. New adjuvant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500437B1 (en) * 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
IL143956A0 (en) * 1998-12-23 2002-04-21 Leti Lab Chimeric gene encoding the antigenic determinants of four proteins of l.infantum
ES2169995B1 (en) * 2000-04-17 2003-12-01 Leti Lab LIP2A PROTEIN BASED COMPOSITION AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT TO PROVIDE AN IMMUNE RESPONSE AGAINST AN ANTIGEN.
US20030072714A1 (en) * 2001-10-12 2003-04-17 Magill Alan J. Microfluidized leishmania lysate and methods of making and using thereof

Also Published As

Publication number Publication date
CN101977930A (en) 2011-02-16
HK1150291A1 (en) 2011-11-18
BRPI0906787A2 (en) 2015-08-18
PL2231700T3 (en) 2014-09-30
HRP20140447T1 (en) 2014-07-04
CN101977930B (en) 2014-12-17
JP2011509968A (en) 2011-03-31
CA2712475A1 (en) 2009-07-23
AP2010005333A0 (en) 2010-08-31
RU2010134427A (en) 2012-02-27
MX2010007831A (en) 2011-06-20
EP2231700A1 (en) 2010-09-29
AU2009204849B2 (en) 2013-10-03
ZA201005143B (en) 2011-12-28
AU2009204849A1 (en) 2009-07-23
AP3007A (en) 2014-10-31
PT2231700E (en) 2014-07-31
EP2231700B1 (en) 2014-05-07
CO6280495A2 (en) 2011-05-20
US20110020405A1 (en) 2011-01-27
EP2570427A1 (en) 2013-03-20
ES2486365T3 (en) 2014-08-18
WO2009090175A1 (en) 2009-07-23
JP2015180638A (en) 2015-10-15
DK2231700T3 (en) 2014-07-14
RU2521499C2 (en) 2014-06-27

Similar Documents

Publication Publication Date Title
MA29406B1 (en) ALPHA TOXOID VACCINE BY C. PERFRINGENS
MA28149A1 (en) VACCINE COMPOSITIONS COMPRISING AN INTERLEUKIN 18 AND A SAPONINE-LIKE ADJUVANT SYSTEM
MA47313B1 (en) Her2 antibody subcutaneous formulations
MA30298B1 (en) COMPOSITION
MA30866B1 (en) VACCINE
WO2008014979A3 (en) NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
MA33449B1 (en) RECOMBINANT ANTIGENS OF THE VRS
BRPI0409459A (en) New Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
MX2010008468A (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlX<sub >mGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS.
BR0212999A (en) New Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
MX2009006760A (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
BRPI0510430A (en) compositions and methods for mucosal vaccination
EA200900024A1 (en) Anti-throat vaccine
MA30343B1 (en) IMMUNOGENIC COMPOSITION
MA32226B1 (en) Compositions and their methods of preparation and use
MA34019B1 (en) ARYLTRIAZOLONE RELATED TO A BIS-ARYL AND USE THEREOF
TN2011000353A1 (en) DERIVATIVES OF THIADIAZOLES AND OXADIAZOLES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
EA200701113A1 (en) Macrolides
UA100507C2 (en) Prevention and treatment of sub-clinical pcvd
MA35513B1 (en) Pharmaceutical compositions comprising 40 - o - (2 - hydroxy) ethyl - rapamycin
MA33419B1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
EA202091690A1 (en) IMMUNOGENIC COMPOSITION CONTAINING STAPHYLOCOCCAL ANTIGENS
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
MA33813B1 (en) USE OF A SOURCE OF L3 AND / OR L5 AS A VACCINE OR AS A DIAGNOSIS FOR PARASITIC DISEASE